Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide

[1] Sekeres MA(2008)Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes J Clin Oncol 26 5943-5949

[2] Maciejewski JP(2006)Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion N Engl J Med 355 1456-1465

[3] Giagounidis AA(2005)Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study Ann Hematol 84 389-394

[4] Wride K(2008)Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes Ann Hematol 87 345-352

[5] Knight R(2010)Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression Ann Hematol 89 365-374

[6] Raza A(2010)Persistent malignant stem cells in del(5q) myelodysplasia in remission N Engl J Med 363 1025-1037

[7] List A(2009)The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells Haematologica 94 430-431

[8] Dewald G(2010)Short telomeres before lenalidomide treatment predict leukemic progression in patients with myelodysplastic syndrome and deletion 5q Blood 116 30-1766

[9] Bennett J(2009)Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression Haematologica 94 1762-98

[10] Giagounidis A(2001)Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin′s lymphoma Leuk Res 25 95-120

[1] Sekeres MA(2008)Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes J Clin Oncol 26 5943-5949

[2] Maciejewski JP(2006)Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion N Engl J Med 355 1456-1465

[3] Giagounidis AA(2005)Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study Ann Hematol 84 389-394

[4] Wride K(2008)Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes Ann Hematol 87 345-352

[5] Knight R(2010)Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression Ann Hematol 89 365-374

[6] Raza A(2010)Persistent malignant stem cells in del(5q) myelodysplasia in remission N Engl J Med 363 1025-1037

[7] List A(2009)The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells Haematologica 94 430-431

[8] Dewald G(2010)Short telomeres before lenalidomide treatment predict leukemic progression in patients with myelodysplastic syndrome and deletion 5q Blood 116 30-1766

[9] Bennett J(2009)Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression Haematologica 94 1762-98

[10] Giagounidis A(2001)Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin′s lymphoma Leuk Res 25 95-120